Difference between revisions of "Penile cancer"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "https://www.europeanurology.com/article/S0302-2838(11)00896-7" to "https://doi.org/10.1016/j.eururo.2011.08.028")
m
Line 10: Line 10:
 
|}
 
|}
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
 
 
=Guidelines=
 
=Guidelines=
 
==[http://www.esmo.org/ ESMO]==
 
==[http://www.esmo.org/ ESMO]==
 
*'''2013:''' Van Poppel et al. [https://www.esmo.org/Guidelines/Genitourinary-Cancers/Penile-Carcinoma Penile cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up]
 
*'''2013:''' Van Poppel et al. [https://www.esmo.org/Guidelines/Genitourinary-Cancers/Penile-Carcinoma Penile cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up]
 
 
==[https://www.nccn.org/ NCCN]==
 
==[https://www.nccn.org/ NCCN]==
 
*[https://www.nccn.org/professionals/physician_gls/pdf/penile.pdf NCCN Guidelines - Penile Cancer]
 
*[https://www.nccn.org/professionals/physician_gls/pdf/penile.pdf NCCN Guidelines - Penile Cancer]
 
 
=Neoadjuvant chemotherapy=
 
=Neoadjuvant chemotherapy=
 
 
==TIP {{#subobject:fe995|Regimen=1}}==
 
==TIP {{#subobject:fe995|Regimen=1}}==
 
 
TIP: '''<u>T</u>'''axol (Paclitaxel), '''<u>I</u>'''fosfamide, '''<u>P</u>'''latinol (Cisplatin)
 
TIP: '''<u>T</u>'''axol (Paclitaxel), '''<u>I</u>'''fosfamide, '''<u>P</u>'''latinol (Cisplatin)
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:b81dfa|Variant=1}}===
 
===Regimen {{#subobject:b81dfa|Variant=1}}===
 
{| class="wikitable" style="width: 40%; text-align:center;"  
 
{| class="wikitable" style="width: 40%; text-align:center;"  
Line 33: Line 29:
 
|}
 
|}
 
''Note: cycle was repeated on day 22 if the patient's ANC was at least 1400/uL and platelet count was at least 100 x 10<sup>9</sup>/L.''
 
''Note: cycle was repeated on day 22 if the patient's ANC was at least 1400/uL and platelet count was at least 100 x 10<sup>9</sup>/L.''
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1
 
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1
Line 38: Line 35:
 
*[[Cisplatin (Platinol)]] 25 mg/m<sup>2</sup> IV over 2 hours once per day on days 1 to 3
 
*[[Cisplatin (Platinol)]] 25 mg/m<sup>2</sup> IV over 2 hours once per day on days 1 to 3
 
**Administered intravenously in 250 mL of normal saline containing 12.5 g of mannitol
 
**Administered intravenously in 250 mL of normal saline containing 12.5 g of mannitol
 
 
====Supportive therapy====
 
====Supportive therapy====
 
*[[Mesna (Mesnex)]] as follows:
 
*[[Mesna (Mesnex)]] as follows:
Line 53: Line 49:
 
**[[Famotidine (Pepcid)]] 20 mg IV once on day 1, prior to [[Paclitaxel (Taxol)]]
 
**[[Famotidine (Pepcid)]] 20 mg IV once on day 1, prior to [[Paclitaxel (Taxol)]]
 
*"The use of prophylactic G-CSF was allowed but not required"
 
*"The use of prophylactic G-CSF was allowed but not required"
 
 
'''21- to 28-day cycle for 4 cycles'''
 
'''21- to 28-day cycle for 4 cycles'''
 
+
</div>
 +
<div class="toccolours" style="background-color:#cbd5e7">
 
====Subsequent treatment====
 
====Subsequent treatment====
 
*[[Surgery#Surgical_resection|Surgery]]
 
*[[Surgery#Surgical_resection|Surgery]]
 
+
</div></div>
 
===References===
 
===References===
 
# '''MDACC ID99-194:''' Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010 Aug 20;28(24):3851-7. Epub 2010 Jul 12. [https://doi.org/10.1200/jco.2010.29.5477 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940402/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20625118 PubMed] NCT00512096
 
# '''MDACC ID99-194:''' Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010 Aug 20;28(24):3851-7. Epub 2010 Jul 12. [https://doi.org/10.1200/jco.2010.29.5477 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940402/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20625118 PubMed] NCT00512096
 
 
==VBM (Vincristine) {{#subobject:fdb0db|Regimen=1}}==
 
==VBM (Vincristine) {{#subobject:fdb0db|Regimen=1}}==
 
 
VBM: '''<u>V</u>'''incristine, '''<u>B</u>'''leomycin, '''<u>M</u>'''ethotrexate
 
VBM: '''<u>V</u>'''incristine, '''<u>B</u>'''leomycin, '''<u>M</u>'''ethotrexate
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:a25051|Variant=1}}===
 
===Regimen {{#subobject:a25051|Variant=1}}===
 
{| class="wikitable" style="width: 40%; text-align:center;"  
 
{| class="wikitable" style="width: 40%; text-align:center;"  
Line 75: Line 70:
 
|}
 
|}
 
''Note: this is of historic interest given the toxicity of bleomycin-containing regimens.''
 
''Note: this is of historic interest given the toxicity of bleomycin-containing regimens.''
 +
<div class="toccolours" style="background-color:#cbd5e8">
 
====Preceding treatment====
 
====Preceding treatment====
 
*[[Surgery#Surgical_resection|Surgery]], within 2 to 4 weeks
 
*[[Surgery#Surgical_resection|Surgery]], within 2 to 4 weeks
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Vincristine (Oncovin)]] 1 mg IV once per day on days 1, 8, 15
 
*[[Vincristine (Oncovin)]] 1 mg IV once per day on days 1, 8, 15
 
*[[Bleomycin (Blenoxane)]] 15 mg IM once per day on days 1, 2, 8, 9, 15, 16, '''given 6 hours and 24 hours after vincristine'''
 
*[[Bleomycin (Blenoxane)]] 15 mg IM once per day on days 1, 2, 8, 9, 15, 16, '''given 6 hours and 24 hours after vincristine'''
 
*[[Methotrexate (MTX)]] 30 mg PO once per day on days 3, 10, 17, '''given 48 hours after vincristine'''
 
*[[Methotrexate (MTX)]] 30 mg PO once per day on days 3, 10, 17, '''given 48 hours after vincristine'''
 
 
'''21-day cycle for 4 cycles'''
 
'''21-day cycle for 4 cycles'''
 +
</div>
 +
<div class="toccolours" style="background-color:#cbd5e7">
 
====Subsequent treatment====
 
====Subsequent treatment====
 
*[[Surgery#Surgical_resection|Surgery]]
 
*[[Surgery#Surgical_resection|Surgery]]
 +
</div></div>
 
===References===
 
===References===
 
# Pizzocaro G, Piva L. Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol. 1988;27(6b):823-4. [http://www.tandfonline.com/doi/full/10.3109/02841868809094366 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/2466471 PubMed]  
 
# Pizzocaro G, Piva L. Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol. 1988;27(6b):823-4. [http://www.tandfonline.com/doi/full/10.3109/02841868809094366 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/2466471 PubMed]  
 
# '''Review:''' Pagliaro LC, Crook J. Multimodality therapy in penile cancer: when and which treatments? World J Urol. 2009 Apr;27(2):221-5. Epub 2008 Aug 6. [http://link.springer.com/article/10.1007/s00345-008-0310-z link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164341/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/18682961 PubMed]
 
# '''Review:''' Pagliaro LC, Crook J. Multimodality therapy in penile cancer: when and which treatments? World J Urol. 2009 Apr;27(2):221-5. Epub 2008 Aug 6. [http://link.springer.com/article/10.1007/s00345-008-0310-z link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164341/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/18682961 PubMed]
 
 
=Adjuvant chemotherapy=
 
=Adjuvant chemotherapy=
 
==DCF {{#subobject:118691|Regimen=1}}==
 
==DCF {{#subobject:118691|Regimen=1}}==
 
 
DCF: '''<u>D</u>'''ocetaxel, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil
 
DCF: '''<u>D</u>'''ocetaxel, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:a57146|Variant=1}}===
 
===Regimen {{#subobject:a57146|Variant=1}}===
 
{| class="wikitable" style="width: 40%; text-align:center;"  
 
{| class="wikitable" style="width: 40%; text-align:center;"  
Line 102: Line 101:
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#cbd5e8">
 
====Preceding treatment====
 
====Preceding treatment====
 
*[[Surgery#Surgical_resection|Surgery]]
 
*[[Surgery#Surgical_resection|Surgery]]
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
 
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
 
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
 
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
 
*[[Fluorouracil (5-FU)]] 750 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 3000 mg/m<sup>2</sup>)
 
*[[Fluorouracil (5-FU)]] 750 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 3000 mg/m<sup>2</sup>)
 
 
'''21-day cycle for 3 cycles'''
 
'''21-day cycle for 3 cycles'''
 
+
</div></div>
 
===References===
 
===References===
 
# '''Case report:''' Necchi A, Nicolai N, Colecchia M, Catanzaro M, Torelli T, Piva L, Salvioni R. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol. 2011 Aug 1;29(22):e650-2. Epub 2011 May 31. [https://doi.org/10.1200/jco.2011.34.8367 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/21632506 PubMed]
 
# '''Case report:''' Necchi A, Nicolai N, Colecchia M, Catanzaro M, Torelli T, Piva L, Salvioni R. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol. 2011 Aug 1;29(22):e650-2. Epub 2011 May 31. [https://doi.org/10.1200/jco.2011.34.8367 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/21632506 PubMed]
 
 
==TIP==
 
==TIP==
 
 
TIP: '''<u>T</u>'''axol (Paclitaxel), '''<u>I</u>'''fosfamide, '''<u>P</u>'''latinol (Cisplatin)
 
TIP: '''<u>T</u>'''axol (Paclitaxel), '''<u>I</u>'''fosfamide, '''<u>P</u>'''latinol (Cisplatin)
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen===
 
===Regimen===
 
<br>''Note: No primary reference available, but some guidelines state that it is reasonable to give adjuvant TIP if it was not given preoperatively and pathology shows high-risk features. (see neoadjuvant [[#TIP|TIP for a referenced regimen]])''
 
<br>''Note: No primary reference available, but some guidelines state that it is reasonable to give adjuvant TIP if it was not given preoperatively and pathology shows high-risk features. (see neoadjuvant [[#TIP|TIP for a referenced regimen]])''
 +
<div class="toccolours" style="background-color:#cbd5e8">
 
====Preceding treatment====
 
====Preceding treatment====
 
*[[Surgery#Surgical_resection|Surgery]]
 
*[[Surgery#Surgical_resection|Surgery]]
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Paclitaxel (Taxol)]]
 
*[[Paclitaxel (Taxol)]]
 
*[[Ifosfamide (Ifex)]]
 
*[[Ifosfamide (Ifex)]]
 
*[[Cisplatin (Platinol)]]
 
*[[Cisplatin (Platinol)]]
 +
</div></div>
 
===References===
 
===References===
 
#No primary reference available
 
#No primary reference available
 
 
=Metastatic or unresectable disease=
 
=Metastatic or unresectable disease=
 
 
==BMP {{#subobject:ab9e5f|Regimen=1}}==
 
==BMP {{#subobject:ab9e5f|Regimen=1}}==
 
 
BMP: '''<u>B</u>'''leomycin, '''<u>M</u>'''ethotrexate, '''<u>P</u>'''latinol (Cisplatin)
 
BMP: '''<u>B</u>'''leomycin, '''<u>M</u>'''ethotrexate, '''<u>P</u>'''latinol (Cisplatin)
 
<br>MPB: '''<u>M</u>'''ethotrexate, '''<u>P</u>'''latinol (Cisplatin), '''<u>B</u>'''leomycin
 
<br>MPB: '''<u>M</u>'''ethotrexate, '''<u>P</u>'''latinol (Cisplatin), '''<u>B</u>'''leomycin
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen variant #1 {{#subobject:8938|Variant=1}}===
 
===Regimen variant #1 {{#subobject:8938|Variant=1}}===
 
{| class="wikitable" style="width: 40%; text-align:center;"  
 
{| class="wikitable" style="width: 40%; text-align:center;"  
Line 143: Line 145:
 
|-
 
|-
 
|}
 
|}
''This is likely of historic interest due to the toxicity of bleomycin-containing regimens. Bleomycin was discontinued when a total cumulative dose of 200 units/m<sup>2</sup> was reached.''
+
''Note: This is likely of historic interest due to the toxicity of bleomycin-containing regimens. Bleomycin was discontinued when a total cumulative dose of 200 units/m<sup>2</sup> was reached.''
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Bleomycin (Blenoxane)]] as follows:
 
*[[Bleomycin (Blenoxane)]] as follows:
Line 149: Line 152:
 
*[[Methotrexate (MTX)]] 25 mg/m<sup>2</sup> IV bolus once per day on days 1 & 8
 
*[[Methotrexate (MTX)]] 25 mg/m<sup>2</sup> IV bolus once per day on days 1 & 8
 
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1, given at a rate of 1 mg/min
 
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1, given at a rate of 1 mg/min
 
 
====Supportive therapy====
 
====Supportive therapy====
 
*Normal saline IV at 250 mL/hour, starting 1 hour before [[Cisplatin (Platinol)]] and continued for at least 6 hours after completion of [[Cisplatin (Platinol)]]
 
*Normal saline IV at 250 mL/hour, starting 1 hour before [[Cisplatin (Platinol)]] and continued for at least 6 hours after completion of [[Cisplatin (Platinol)]]
 
*[[Furosemide (Lasix)]] 40 mg IV once on day 1, given prior to [[Cisplatin (Platinol)]]
 
*[[Furosemide (Lasix)]] 40 mg IV once on day 1, given prior to [[Cisplatin (Platinol)]]
 
 
'''21-day cycles (patients who achieved CR discontinued therapy after 6 cycles)'''
 
'''21-day cycles (patients who achieved CR discontinued therapy after 6 cycles)'''
 
+
</div></div><br>
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen variant #2 {{#subobject:99e731|Variant=1}}===
 
===Regimen variant #2 {{#subobject:99e731|Variant=1}}===
 
{| class="wikitable" style="width: 40%; text-align:center;"  
 
{| class="wikitable" style="width: 40%; text-align:center;"  
Line 165: Line 167:
 
|-
 
|-
 
|}
 
|}
''21 of 29 evaluable patients in Corral et al. 1998 had penile cancer. Please see the paper for additional variations in the protocol, including some patients being treated with intraarterial therapy. This is likely of historic interest due to the toxicity of bleomycin-containing regimens.''  
+
''Note: 21 of 29 evaluable patients in Corral et al. 1998 had penile cancer. Please see the paper for additional variations in the protocol, including some patients being treated with intraarterial therapy. This is likely of historic interest due to the toxicity of bleomycin-containing regimens.''  
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Bleomycin (Blenoxane)]] 10 mg/m<sup>2</sup> IV once per day on days 2 to 6  
 
*[[Bleomycin (Blenoxane)]] 10 mg/m<sup>2</sup> IV once per day on days 2 to 6  
Line 172: Line 175:
 
*[[Cisplatin (Platinol)]] 20 mg/m<sup>2</sup> IV over 3 hours once per day on days 2 to 6
 
*[[Cisplatin (Platinol)]] 20 mg/m<sup>2</sup> IV over 3 hours once per day on days 2 to 6
 
**Note: Corral et al. 1998 does not specify which days cisplatin is given on. Pagliaro et al. 2009 specifies that cisplatin is given on days 2 to 6. For Corral et al. 1998, the 5 day course is inferred based on the paper saying that the total dosage--presumably per cycle--was 100 mg/m<sup>2</sup>.
 
**Note: Corral et al. 1998 does not specify which days cisplatin is given on. Pagliaro et al. 2009 specifies that cisplatin is given on days 2 to 6. For Corral et al. 1998, the 5 day course is inferred based on the paper saying that the total dosage--presumably per cycle--was 100 mg/m<sup>2</sup>.
 
 
====Supportive therapy====
 
====Supportive therapy====
 
*[[Folinic acid (Leucovorin)]] 25 mg PO every 6 hours on days 2 to 4, 16 to 18, 23 to 25, starting 24 hours after each dose of [[Methotrexate (MTX)]]
 
*[[Folinic acid (Leucovorin)]] 25 mg PO every 6 hours on days 2 to 4, 16 to 18, 23 to 25, starting 24 hours after each dose of [[Methotrexate (MTX)]]
 
 
'''28-day cycles'''
 
'''28-day cycles'''
 
+
</div></div>
 
===References===
 
===References===
 
# Corral DA, Sella A, Pettaway CA, Amato RJ, Jones DM, Ellerhorst J. Combination chemotherapy for metastatic or locally advanced genitourinary squamous cell carcinoma: a phase II study of methotrexate, cisplatin and bleomycin. J Urol. 1998 Nov;160(5):1770-4. [http://www.auajournals.org/article/S0022-5347%2801)62402-9 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/9783949 PubMed]
 
# Corral DA, Sella A, Pettaway CA, Amato RJ, Jones DM, Ellerhorst J. Combination chemotherapy for metastatic or locally advanced genitourinary squamous cell carcinoma: a phase II study of methotrexate, cisplatin and bleomycin. J Urol. 1998 Nov;160(5):1770-4. [http://www.auajournals.org/article/S0022-5347%2801)62402-9 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/9783949 PubMed]
 
# Haas GP, Blumenstein BA, Gagliano RG, Russell CA, Rivkin SE, Culkin DJ, Wolf M, Crawford ED. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol. 1999 Jun;161(6):1823-5. [http://www.auajournals.org/article/S0022-5347(05)68815-5 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/10332445 PubMed] content property of [http://hemonc.org HemOnc.org]
 
# Haas GP, Blumenstein BA, Gagliano RG, Russell CA, Rivkin SE, Culkin DJ, Wolf M, Crawford ED. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol. 1999 Jun;161(6):1823-5. [http://www.auajournals.org/article/S0022-5347(05)68815-5 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/10332445 PubMed] content property of [http://hemonc.org HemOnc.org]
 
# '''Review:''' Pagliaro LC, Crook J. Multimodality therapy in penile cancer: when and which treatments? World J Urol. 2009 Apr;27(2):221-5. Epub 2008 Aug 6. [http://link.springer.com/article/10.1007/s00345-008-0310-z link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164341/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/18682961 PubMed]
 
# '''Review:''' Pagliaro LC, Crook J. Multimodality therapy in penile cancer: when and which treatments? World J Urol. 2009 Apr;27(2):221-5. Epub 2008 Aug 6. [http://link.springer.com/article/10.1007/s00345-008-0310-z link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164341/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/18682961 PubMed]
 
 
==Cisplatin & Fluorouracil (CF) {{#subobject:f70357|Regimen=1}}==
 
==Cisplatin & Fluorouracil (CF) {{#subobject:f70357|Regimen=1}}==
 
+
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:1e2b1c|Variant=1}}===
 
===Regimen {{#subobject:1e2b1c|Variant=1}}===
 
{| class="wikitable" style="width: 40%; text-align:center;"  
 
{| class="wikitable" style="width: 40%; text-align:center;"  
Line 194: Line 194:
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 1
 
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 1
 
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 5000 mg/m<sup>2</sup>)
 
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 5000 mg/m<sup>2</sup>)
 
+
</div></div>
 
===References===
 
===References===
 
# Shammas FV, Ous S, Fossa SD. Cisplatin and 5-fluorouracil in advanced cancer of the penis. J Urol. 1992 Mar;147(3):630-2. [https://doi.org/10.1016/s0022-5347(17)37327-5 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/1538445 PubMed]
 
# Shammas FV, Ous S, Fossa SD. Cisplatin and 5-fluorouracil in advanced cancer of the penis. J Urol. 1992 Mar;147(3):630-2. [https://doi.org/10.1016/s0022-5347(17)37327-5 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/1538445 PubMed]
 
 
==Cisplatin & Irinotecan (IC) {{#subobject:606813|Regimen=1}}==
 
==Cisplatin & Irinotecan (IC) {{#subobject:606813|Regimen=1}}==
 
+
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:ec3985|Variant=1}}===
 
===Regimen {{#subobject:ec3985|Variant=1}}===
 
{| class="wikitable" style="width: 40%; text-align:center;"  
 
{| class="wikitable" style="width: 40%; text-align:center;"  
Line 212: Line 212:
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV over 1 to 3 hours once on day 1, '''given second'''
 
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV over 1 to 3 hours once on day 1, '''given second'''
 
*[[Irinotecan (Camptosar)]] 60 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15, '''given first'''
 
*[[Irinotecan (Camptosar)]] 60 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15, '''given first'''
 
 
====Supportive therapy====
 
====Supportive therapy====
 
*Adequate hydration with cisplatin, per guidelines at each investigator's site
 
*Adequate hydration with cisplatin, per guidelines at each investigator's site
 
*Antiemetic medication per routine local practice.  
 
*Antiemetic medication per routine local practice.  
 
*"Systematic premedication with atropine as of the first cycle of treatment was at the investigator's discretion but was not recommended."
 
*"Systematic premedication with atropine as of the first cycle of treatment was at the investigator's discretion but was not recommended."
 
 
'''28-day cycles, with up to 4 cycles before surgery in the neoadjuvant setting for T3 or N1 to N2; up to 8 cycles for patients with T4, N3, or M+ distant metastatic disease'''
 
'''28-day cycles, with up to 4 cycles before surgery in the neoadjuvant setting for T3 or N1 to N2; up to 8 cycles for patients with T4, N3, or M+ distant metastatic disease'''
 
+
</div></div>
 
===References===
 
===References===
 
# Theodore C, Skoneczna I, Bodrogi I, Leahy M, Kerst JM, Collette L, Ven K, Marréaud S, Oliver RD; [[Study_Groups#EORTC|EORTC]] Genito-Urinary Tract Cancer Group. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol. 2008 Jul;19(7):1304-7. [https://doi.org/10.1093/annonc/mdn149 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/18417462 PubMed]
 
# Theodore C, Skoneczna I, Bodrogi I, Leahy M, Kerst JM, Collette L, Ven K, Marréaud S, Oliver RD; [[Study_Groups#EORTC|EORTC]] Genito-Urinary Tract Cancer Group. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol. 2008 Jul;19(7):1304-7. [https://doi.org/10.1093/annonc/mdn149 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/18417462 PubMed]
 
 
==Paclitaxel monotherapy {{#subobject:3bde8f|Regimen=1}}==
 
==Paclitaxel monotherapy {{#subobject:3bde8f|Regimen=1}}==
 
+
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:2565c5|Variant=1}}===
 
===Regimen {{#subobject:2565c5|Variant=1}}===
 
{| class="wikitable" style="width: 40%; text-align:center;"  
 
{| class="wikitable" style="width: 40%; text-align:center;"  
Line 237: Line 235:
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1
 
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1
 
 
====Supportive therapy====
 
====Supportive therapy====
 
*[[:Category:Granulocyte colony-stimulating factors|G-CSF]] could be used in later cycles if the patient developed febrile neutropenia during treatment
 
*[[:Category:Granulocyte colony-stimulating factors|G-CSF]] could be used in later cycles if the patient developed febrile neutropenia during treatment
 
*[[Dexamethasone (Decadron)]] 8 mg PO given three times, at 12 hours before, immediately before, and 12 hours after paclitaxel
 
*[[Dexamethasone (Decadron)]] 8 mg PO given three times, at 12 hours before, immediately before, and 12 hours after paclitaxel
 
 
'''21-day cycles'''
 
'''21-day cycles'''
 
+
</div></div>
 
===References===
 
===References===
 
# Di Lorenzo G, Federico P, Buonerba C, Longo N, Cartenì G, Autorino R, Perdonà S, Ferro M, Rescigno P, D'Aniello C, Matano E, Altieri V, Palmieri G, Imbimbo C, De Placido S, Mirone V. Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. Eur Urol. 2011 Dec;60(6):1280-4. [https://doi.org/10.1016/j.eururo.2011.08.028 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/21871710 PubMed]
 
# Di Lorenzo G, Federico P, Buonerba C, Longo N, Cartenì G, Autorino R, Perdonà S, Ferro M, Rescigno P, D'Aniello C, Matano E, Altieri V, Palmieri G, Imbimbo C, De Placido S, Mirone V. Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. Eur Urol. 2011 Dec;60(6):1280-4. [https://doi.org/10.1016/j.eururo.2011.08.028 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/21871710 PubMed]
 
 
==Panitumumab monotherapy {{#subobject:92a67f|Regimen=1}}==
 
==Panitumumab monotherapy {{#subobject:92a67f|Regimen=1}}==
 
+
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:7d9cd7|Variant=1}}===
 
===Regimen {{#subobject:7d9cd7|Variant=1}}===
 
{| class="wikitable" style="width: 40%; text-align:center;"  
 
{| class="wikitable" style="width: 40%; text-align:center;"  
Line 260: Line 256:
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Targeted therapy====
 
====Targeted therapy====
 
*[[Panitumumab (Vectibix)]] 6 mg/kg IV once on day 1
 
*[[Panitumumab (Vectibix)]] 6 mg/kg IV once on day 1
 
 
'''14-day cycles'''
 
'''14-day cycles'''
 
+
</div></div>
 
===References===
 
===References===
 
# '''Case report:''' Necchi A, Nicolai N, Colecchia M, Catanzaro M, Torelli T, Piva L, Salvioni R. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol. 2011 Aug 1;29(22):e650-2. Epub 2011 May 31. [https://doi.org/10.1200/jco.2011.34.8367 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/21632506 PubMed]
 
# '''Case report:''' Necchi A, Nicolai N, Colecchia M, Catanzaro M, Torelli T, Piva L, Salvioni R. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol. 2011 Aug 1;29(22):e650-2. Epub 2011 May 31. [https://doi.org/10.1200/jco.2011.34.8367 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/21632506 PubMed]
 
 
==PCF {{#subobject:edc2a7|Regimen=1}}==
 
==PCF {{#subobject:edc2a7|Regimen=1}}==
 
 
PCF: '''<u>P</u>'''aclitaxel, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil
 
PCF: '''<u>P</u>'''aclitaxel, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:5f8356|Variant=1}}===
 
===Regimen {{#subobject:5f8356|Variant=1}}===
 
{| class="wikitable" style="width: 40%; text-align:center;"  
 
{| class="wikitable" style="width: 40%; text-align:center;"  
Line 280: Line 275:
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Paclitaxel (Taxol)]] 120 mg/m<sup>2</sup> IV once on day 1, '''given first'''
 
*[[Paclitaxel (Taxol)]] 120 mg/m<sup>2</sup> IV once on day 1, '''given first'''
 
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV once per day on days 1 & 2
 
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV once per day on days 1 & 2
 
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 2 (total dose per cycle: 4000 mg/m<sup>2</sup>)
 
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 2 (total dose per cycle: 4000 mg/m<sup>2</sup>)
 
 
====Supportive therapy====
 
====Supportive therapy====
 
*"Corticosteroids, antihistamines, and an H2 antagonist were administered before starting paclitaxel"
 
*"Corticosteroids, antihistamines, and an H2 antagonist were administered before starting paclitaxel"
 
*"Antiemetic drugs and glutathione were administered before [[Cisplatin (Platinol)]]"
 
*"Antiemetic drugs and glutathione were administered before [[Cisplatin (Platinol)]]"
 
*1 liter half normal 2.5% glucose saline with 20 mEq potassium chloride and 10 mEq magnesium sulfate (MgSO4) IV given twice, before and after [[Cisplatin (Platinol)]]
 
*1 liter half normal 2.5% glucose saline with 20 mEq potassium chloride and 10 mEq magnesium sulfate (MgSO4) IV given twice, before and after [[Cisplatin (Platinol)]]
 
 
'''21-day cycles'''; "two patients received more than the standard four courses"
 
'''21-day cycles'''; "two patients received more than the standard four courses"
 
+
</div></div>
 
===References===
 
===References===
 
# Pizzocaro G, Nicolai N, Milani A. Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol. 2009 Mar;55(3):546-51. Epub 2008 Jul 14. [https://doi.org/10.1016/j.eururo.2008.07.014 link to original article] [https://pubmed.ncbi.nlm.nih.gov/18649992 PubMed]
 
# Pizzocaro G, Nicolai N, Milani A. Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol. 2009 Mar;55(3):546-51. Epub 2008 Jul 14. [https://doi.org/10.1016/j.eururo.2008.07.014 link to original article] [https://pubmed.ncbi.nlm.nih.gov/18649992 PubMed]
 
 
==TIP {{#subobject:2169d9|Regimen=1}}==
 
==TIP {{#subobject:2169d9|Regimen=1}}==
 
 
TIP: '''<u>T</u>'''axol (Paclitaxel), '''<u>I</u>'''fosfamide, '''<u>P</u>'''latinol (Cisplatin)
 
TIP: '''<u>T</u>'''axol (Paclitaxel), '''<u>I</u>'''fosfamide, '''<u>P</u>'''latinol (Cisplatin)
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen===
 
===Regimen===
 
<br>''Note: No primary reference available, but some guidelines state that it is reasonable to give TIP as first-line therapy for metastatic penile cancer (see neoadjuvant [[#TIP|TIP for a referenced regimen]])''
 
<br>''Note: No primary reference available, but some guidelines state that it is reasonable to give TIP as first-line therapy for metastatic penile cancer (see neoadjuvant [[#TIP|TIP for a referenced regimen]])''
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Paclitaxel (Taxol)]]
 
*[[Paclitaxel (Taxol)]]
 
*[[Ifosfamide (Ifex)]]
 
*[[Ifosfamide (Ifex)]]
 
*[[Cisplatin (Platinol)]]
 
*[[Cisplatin (Platinol)]]
 +
</div></div>
 
===References===
 
===References===
 
# No primary reference available
 
# No primary reference available
 
 
[[Category:Penile cancer regimens]]
 
[[Category:Penile cancer regimens]]
 
[[Category:Disease-specific pages]]
 
[[Category:Disease-specific pages]]
 
[[Category:Genitourinary cancers]]
 
[[Category:Genitourinary cancers]]

Revision as of 17:26, 28 February 2023

Section editor transclusions

9 regimens on this page
10 variants on this page


Guidelines

ESMO

NCCN

Neoadjuvant chemotherapy

TIP

TIP: Taxol (Paclitaxel), Ifosfamide, Platinol (Cisplatin)

Regimen

Study Evidence
Pagliaro et al. 2010 (MDACC ID99-194) Phase 2

Note: cycle was repeated on day 22 if the patient's ANC was at least 1400/uL and platelet count was at least 100 x 109/L.

Chemotherapy

  • Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1
  • Ifosfamide (Ifex) 1200 mg/m2 IV over 2 hours once per day on days 1 to 3
  • Cisplatin (Platinol) 25 mg/m2 IV over 2 hours once per day on days 1 to 3
    • Administered intravenously in 250 mL of normal saline containing 12.5 g of mannitol

Supportive therapy

21- to 28-day cycle for 4 cycles

Subsequent treatment

References

  1. MDACC ID99-194: Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010 Aug 20;28(24):3851-7. Epub 2010 Jul 12. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00512096

VBM (Vincristine)

VBM: Vincristine, Bleomycin, Methotrexate

Regimen

Study Evidence
Pizzocaro et al. 1988 Pilot, <20 pts

Note: this is of historic interest given the toxicity of bleomycin-containing regimens.

Preceding treatment

Chemotherapy

21-day cycle for 4 cycles

Subsequent treatment

References

  1. Pizzocaro G, Piva L. Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol. 1988;27(6b):823-4. link to original article contains dosing details in manuscript PubMed
  2. Review: Pagliaro LC, Crook J. Multimodality therapy in penile cancer: when and which treatments? World J Urol. 2009 Apr;27(2):221-5. Epub 2008 Aug 6. link to original article contains dosing details in manuscript link to PMC article PubMed

Adjuvant chemotherapy

DCF

DCF: Docetaxel, Cisplatin, Fluorouracil

Regimen

Study Evidence
Necchi et al. 2011 Case report

Preceding treatment

Chemotherapy

21-day cycle for 3 cycles

References

  1. Case report: Necchi A, Nicolai N, Colecchia M, Catanzaro M, Torelli T, Piva L, Salvioni R. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol. 2011 Aug 1;29(22):e650-2. Epub 2011 May 31. link to original article contains dosing details in manuscript PubMed

TIP

TIP: Taxol (Paclitaxel), Ifosfamide, Platinol (Cisplatin)

Regimen


Note: No primary reference available, but some guidelines state that it is reasonable to give adjuvant TIP if it was not given preoperatively and pathology shows high-risk features. (see neoadjuvant TIP for a referenced regimen)

Preceding treatment

References

  1. No primary reference available

Metastatic or unresectable disease

BMP

BMP: Bleomycin, Methotrexate, Platinol (Cisplatin)
MPB: Methotrexate, Platinol (Cisplatin), Bleomycin

Regimen variant #1

Study Evidence
Haas et al. 1999 (SWOG 8520) Phase 2

Note: This is likely of historic interest due to the toxicity of bleomycin-containing regimens. Bleomycin was discontinued when a total cumulative dose of 200 units/m2 was reached.

Chemotherapy

Supportive therapy

21-day cycles (patients who achieved CR discontinued therapy after 6 cycles)


Regimen variant #2

Study Evidence
Corral et al. 1998 Phase 2

Note: 21 of 29 evaluable patients in Corral et al. 1998 had penile cancer. Please see the paper for additional variations in the protocol, including some patients being treated with intraarterial therapy. This is likely of historic interest due to the toxicity of bleomycin-containing regimens.

Chemotherapy

  • Bleomycin (Blenoxane) 10 mg/m2 IV once per day on days 2 to 6
    • Note: Pagliaro et al. 2009 lists a "dosage of 50 mg/m2 on days 2 to 6," which could be misinterpreted as 50 mg/m2 for each dose, which is in contrast to the 50 mg/m2 for each cycle that Corral et al. 1998 describes.
  • Methotrexate (MTX) 200 mg/m2 IV once per day on days 1, 15, 22
  • Cisplatin (Platinol) 20 mg/m2 IV over 3 hours once per day on days 2 to 6
    • Note: Corral et al. 1998 does not specify which days cisplatin is given on. Pagliaro et al. 2009 specifies that cisplatin is given on days 2 to 6. For Corral et al. 1998, the 5 day course is inferred based on the paper saying that the total dosage--presumably per cycle--was 100 mg/m2.

Supportive therapy

28-day cycles

References

  1. Corral DA, Sella A, Pettaway CA, Amato RJ, Jones DM, Ellerhorst J. Combination chemotherapy for metastatic or locally advanced genitourinary squamous cell carcinoma: a phase II study of methotrexate, cisplatin and bleomycin. J Urol. 1998 Nov;160(5):1770-4. link to original article contains dosing details in manuscript PubMed
  2. Haas GP, Blumenstein BA, Gagliano RG, Russell CA, Rivkin SE, Culkin DJ, Wolf M, Crawford ED. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol. 1999 Jun;161(6):1823-5. link to original article contains dosing details in manuscript PubMed content property of HemOnc.org
  3. Review: Pagliaro LC, Crook J. Multimodality therapy in penile cancer: when and which treatments? World J Urol. 2009 Apr;27(2):221-5. Epub 2008 Aug 6. link to original article contains dosing details in manuscript link to PMC article PubMed

Cisplatin & Fluorouracil (CF)

Regimen

Study Evidence
Shammas et al. 1992 Pilot, <20 pts

Chemotherapy

References

  1. Shammas FV, Ous S, Fossa SD. Cisplatin and 5-fluorouracil in advanced cancer of the penis. J Urol. 1992 Mar;147(3):630-2. link to original article contains dosing details in abstract PubMed

Cisplatin & Irinotecan (IC)

Regimen

Study Evidence
Theodore et al. 2008 (EORTC 30992) Phase 2

Chemotherapy

Supportive therapy

  • Adequate hydration with cisplatin, per guidelines at each investigator's site
  • Antiemetic medication per routine local practice.
  • "Systematic premedication with atropine as of the first cycle of treatment was at the investigator's discretion but was not recommended."

28-day cycles, with up to 4 cycles before surgery in the neoadjuvant setting for T3 or N1 to N2; up to 8 cycles for patients with T4, N3, or M+ distant metastatic disease

References

  1. Theodore C, Skoneczna I, Bodrogi I, Leahy M, Kerst JM, Collette L, Ven K, Marréaud S, Oliver RD; EORTC Genito-Urinary Tract Cancer Group. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol. 2008 Jul;19(7):1304-7. link to original article contains dosing details in manuscript PubMed

Paclitaxel monotherapy

Regimen

Study Evidence
Di Lorenzo et al. 2011 Phase 2

Chemotherapy

Supportive therapy

  • G-CSF could be used in later cycles if the patient developed febrile neutropenia during treatment
  • Dexamethasone (Decadron) 8 mg PO given three times, at 12 hours before, immediately before, and 12 hours after paclitaxel

21-day cycles

References

  1. Di Lorenzo G, Federico P, Buonerba C, Longo N, Cartenì G, Autorino R, Perdonà S, Ferro M, Rescigno P, D'Aniello C, Matano E, Altieri V, Palmieri G, Imbimbo C, De Placido S, Mirone V. Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. Eur Urol. 2011 Dec;60(6):1280-4. link to original article contains dosing details in manuscript PubMed

Panitumumab monotherapy

Regimen

Study Evidence
Necchi et al. 2011 Case report

Targeted therapy

14-day cycles

References

  1. Case report: Necchi A, Nicolai N, Colecchia M, Catanzaro M, Torelli T, Piva L, Salvioni R. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol. 2011 Aug 1;29(22):e650-2. Epub 2011 May 31. link to original article contains dosing details in manuscript PubMed

PCF

PCF: Paclitaxel, Cisplatin, Fluorouracil

Regimen

Study Evidence
Pizzocaro et al. 2009 Pilot, <20 pts

Chemotherapy

Supportive therapy

  • "Corticosteroids, antihistamines, and an H2 antagonist were administered before starting paclitaxel"
  • "Antiemetic drugs and glutathione were administered before Cisplatin (Platinol)"
  • 1 liter half normal 2.5% glucose saline with 20 mEq potassium chloride and 10 mEq magnesium sulfate (MgSO4) IV given twice, before and after Cisplatin (Platinol)

21-day cycles; "two patients received more than the standard four courses"

References

  1. Pizzocaro G, Nicolai N, Milani A. Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol. 2009 Mar;55(3):546-51. Epub 2008 Jul 14. link to original article PubMed

TIP

TIP: Taxol (Paclitaxel), Ifosfamide, Platinol (Cisplatin)

Regimen


Note: No primary reference available, but some guidelines state that it is reasonable to give TIP as first-line therapy for metastatic penile cancer (see neoadjuvant TIP for a referenced regimen)

References

  1. No primary reference available